TNFRSF9 and lung cancer: Pre-existing ILA changes were described in other malignancies, in a similar percentage, such as in lung cancer observed during screening trials or pretreatment MSCT (7.8% up to 15%) but also locally advanced esophageal cancer (7%) [19,28,29].